NIEHS Funds Six-Member Toxicogenomics Consortium

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

RESEARCH TRIANGLE, North Carolina-Five academic research centers will join the National Institute of Environmental Health Sciences (NIEHS) to form a consortium to study how genes interact with the environment to cause cancer and other

RESEARCH TRIANGLE, North Carolina—Five academic research centers will join the National Institute of Environmental Health Sciences (NIEHS) to form a consortium to study how genes interact with the environment to cause cancer and other diseases, an emerging field known as toxicogenomics. Each of the groups in the 5-year, $37 million program funded by the NIEHS will receive grants totaling more than $7 million.

The consortium will work with NIEHS scientists and use genomics to determine how disease occurs, identify potential environmental hazards, predict potential disease, identify exposed individuals, and prevent disease. The consortium members and their projects are as follows:

NIEHS: gene expression profiling to explore environmental stresses on human health. This research group will make use of gene expression microarray technology validation studies.

University of North Carolina at Chapel Hill: the study of susceptibility factors in the genomic response to toxicants.

Fred Hutchinson Cancer Research Center: gene expression profiling in transgenic mice and rats, and in human cell lines exposed to environmentally relevant agents.

Oregon Health and Science University: cell-specific injury in the central nervous system and gene profiling of induction mechanisms associated with neurotoxicant exposures.

Duke University: gene expression profiling to explore environmental stresses on human health.

Massachusetts Institute of Technology: gene expression profiling to explore environmental alkylating agents stresses on human health. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content